

Amendment No. 3 to SB2257

**Yarbro
Signature of Sponsor**

AMEND Senate Bill No. 2257

House Bill No. 1831*

by inserting the following new section immediately preceding the last section and renumbering the subsequent section accordingly:

SECTION _____. Notwithstanding any law to the contrary, no state entity shall establish through rule or otherwise a preference for a FDA-approved medication used to treat opioid use disorder over any other FDA-approved medication used to treat opioid use disorder. For purposes of this section, "preference" includes prior authorization, a fail-first policy, reimbursement rates, and any other state action that has the effect of diminishing parity among FDA-approved medications to treat opioid use disorder in this state.